Healthcare Industry News: mitral valve
News Release - September 13, 2007
Sorin Group: Celebrates 30 Years of Clinical Use of Its Heart Valves and Highlights Activities at EACTS 2007Sorin Group is Proud to Announce 30 Years of Clinical Use of Its Mechanical Valves, 25 Years of Clinical Use of Mitroflow Pericardial Valves and over 38 Years of Valve Manufacturing
GENEVA--(HSMN NewsFeed)--The Sorin Group (MIL:SRN) celebrates 30 years of clinical use of its mechanical heart valves and more importantly 25 years of clinical use of its tissue valves at this year's EACTS Congress. The Group has organized a series of presentations and symposia to highlight its worldwide leadership in heart valves.
Headquartered in Milan, Sorin is Europe's largest research center for heart-valve development and is at the cutting-edge in bringing new technology to the world of bio-medicine.
"Indisputable hemodynamic performance, absolute biocompatibility and proven long-term clinical outcomes are the results of over 38 years experience in the manufacturing of mechanical valves and more than 25 years experience in harvesting, selecting and treating bovine pericardium for the manufacture of tissue valves," said Franco Vallana, Sorin Group Chief Scientific Officer.
Below is the history and evolution of Sorin's success in heart valve development:
In 1982, the Mitroflow pericardial valves were introduced in the market, proof of the Sorin Group's expertise in tissue valves.
In 1977, the first Sorin Group mechanical valve was introduced in the market (Monocast).
Pioneers of Pyrolytic carbon Technology since 1969, the Sorin Group has designed and manufactured over 20 different heart valves prostheses for 17 different companies and has manufactured components for over 2.5 million valves sold worldwide.
Sorin Group will celebrate at its booth all of these milestones on September 16 during the grand opening of EACTS and will sponsor the following symposia:
On Monday, September 17 and Tuesday, September 18, two Satellite Symposia will take place from 12:45 p.m. to 2:00 p.m. in Mont Blanc Room at Geneva Palexpo.
On Monday, September 17 at the "Controversial Cases in the Treatment of mitral valve Disease" symposium Drs. Alfieri (Milan, Italy), Calafiore (Catania, Italy) and Lessana (Paris, France) will discuss on several MV cases with the aid of a tele-voting system. This format will make the discussion very interactive with the audience.
On Tuesday, September 18 at the "Treatment of Aortic Valve Disease in High Risk and Elderly Patients" symposium Drs. Cotrufo (Naples, Italy), Pomar (Barcelona, Spain), Glauber (Massa, Italy), Yankah (Berlin, Germany), Haverich (Hanover, Germany) and Bavaria (Philadelphia, USA) will discuss the latest experience in the treatment of those particular patients with the Freedom Solo valve, Mitroflow valve, Sutureless valve and Carbo-Seal Valsalva aorto-valvular prosthesis.
About the Sorin Group
The Sorin Group (Bloomberg: SRN.IM; Reuters: SORN.MI), a world leader in the development of medical technologies for cardiac surgery, offers innovative therapies for cardiac rhythm dysfunctions, interventional cardiology and the treatment of chronic kidney diseases. The Sorin Group includes these brands: Dideco, CarboMedics, COBE Cardiovascular, Stockert, Mitroflow, ELA Medical, Sorin Biomedica, Bellco and Bellco-Soludia. At the Sorin Group 4,500 employees work to serve over 5,000 public and private treatment centers in more than 80 countries throughout the world. For more information, please visit: www.sorin.com
Source: Sorin Group
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.